AstraZeneca's Nexium Patent Remains Valid

Law360, New York (November 19, 2007, 12:00 AM EST) -- The European Patent Office has reportedly ruled that a patent covering AstraZeneca Plc's blockbuster heartburn drug Nexium is still valid in its amended form despite challenges from four generic competitors.

AstraZeneca said Monday that its patent, which covers a proton pump inhibitor used in drugs like Nexium and Losec, will now be valid in Austria, Belgium, Switzerland, Germany, Denmark, Spain, France, the United Kingdom, Greece, Ireland, Italy, Liechtenstein, Luxembourg, Monaco, the Netherlands, Portugal, Sweden, Latvia, Lithuania and Slovenia until 2015.

“AstraZeneca has a comprehensive intellectual property...
To view the full article, register now.